Article
The core domain of hepatitis C virus glycoprotein E2 generates potent cross-neutralizing antibodies in guinea pigs.
Hepatology (Baltimore, Md.) - 1 Apr 2017
Vietheer Patricia T, Boo Irene, Gu Jun, McCaffrey Kathleen, Edwards Stirling, Owczarek Catherine, Hardy Matthew P, Fabri Louis, Center Rob J, Poumbourios Pantelis, Drummer Heidi E
Abstract excerpt
A vaccine that prevents hepatitis C virus (HCV) infection is urgently needed to support an emerging global elimination program. However, vaccine development has been confounded because of HCV's high degree of antigenic variability and the preferential induction of type-specific immune responses with limited potency against heterologous viral strains and genotypes. We showed previously that deletion of the three...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
